Cargando…
Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor
Cervical cancer is one of the most common cancers in women. The development of new therapies with immune checkpoint inhibitors (ICIs) is being investigated for cervical cancer; however, their efficacy is not currently sufficient. Oncolytic virus therapy can increase tumor immunogenicity and enhance...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916424/ https://www.ncbi.nlm.nih.gov/pubmed/36768352 http://dx.doi.org/10.3390/ijms24031988 |
_version_ | 1784886122672816128 |
---|---|
author | Kagabu, Masahiro Yoshino, Naoto Murakami, Kazuyuki Kawamura, Hideki Sasaki, Yutaka Muraki, Yasushi Baba, Tsukasa |
author_facet | Kagabu, Masahiro Yoshino, Naoto Murakami, Kazuyuki Kawamura, Hideki Sasaki, Yutaka Muraki, Yasushi Baba, Tsukasa |
author_sort | Kagabu, Masahiro |
collection | PubMed |
description | Cervical cancer is one of the most common cancers in women. The development of new therapies with immune checkpoint inhibitors (ICIs) is being investigated for cervical cancer; however, their efficacy is not currently sufficient. Oncolytic virus therapy can increase tumor immunogenicity and enhance the antitumor effect of ICIs. In this report, the therapeutic potential of a triple-mutated oncolytic herpes virus (T-01) with an ICI for human papillomavirus (HPV)-related cervical cancer was evaluated using a bilateral syngeneic murine model. The efficacy of intratumoral (i.t.) administration with T-01 and subcutaneous (s.c.) administration of anti-programmed cell death ligand 1 (PD-L1) antibody (Ab) was equivalent to that of anti-PD-L1 Ab alone on the T-01-injected side. Moreover, combination therapy had no significant antitumor effect compared to monotherapy on the T-01-non-injected side. Combination therapy significantly increased the number of tumor specific T cells in the tumor. While T-01 could not be isolated from tumors receiving combination therapy, it could be isolated following T-01 monotherapy. Furthermore, T-01 had a cytotoxic effect on stimulated T cells. These results suggest that T-01 and anti-PD-L1 Ab partially counteract and therefore concomitant administration should be considered with caution. |
format | Online Article Text |
id | pubmed-9916424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99164242023-02-11 Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor Kagabu, Masahiro Yoshino, Naoto Murakami, Kazuyuki Kawamura, Hideki Sasaki, Yutaka Muraki, Yasushi Baba, Tsukasa Int J Mol Sci Article Cervical cancer is one of the most common cancers in women. The development of new therapies with immune checkpoint inhibitors (ICIs) is being investigated for cervical cancer; however, their efficacy is not currently sufficient. Oncolytic virus therapy can increase tumor immunogenicity and enhance the antitumor effect of ICIs. In this report, the therapeutic potential of a triple-mutated oncolytic herpes virus (T-01) with an ICI for human papillomavirus (HPV)-related cervical cancer was evaluated using a bilateral syngeneic murine model. The efficacy of intratumoral (i.t.) administration with T-01 and subcutaneous (s.c.) administration of anti-programmed cell death ligand 1 (PD-L1) antibody (Ab) was equivalent to that of anti-PD-L1 Ab alone on the T-01-injected side. Moreover, combination therapy had no significant antitumor effect compared to monotherapy on the T-01-non-injected side. Combination therapy significantly increased the number of tumor specific T cells in the tumor. While T-01 could not be isolated from tumors receiving combination therapy, it could be isolated following T-01 monotherapy. Furthermore, T-01 had a cytotoxic effect on stimulated T cells. These results suggest that T-01 and anti-PD-L1 Ab partially counteract and therefore concomitant administration should be considered with caution. MDPI 2023-01-19 /pmc/articles/PMC9916424/ /pubmed/36768352 http://dx.doi.org/10.3390/ijms24031988 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kagabu, Masahiro Yoshino, Naoto Murakami, Kazuyuki Kawamura, Hideki Sasaki, Yutaka Muraki, Yasushi Baba, Tsukasa Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor |
title | Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor |
title_full | Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor |
title_fullStr | Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor |
title_full_unstemmed | Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor |
title_short | Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor |
title_sort | treatment of hpv-related uterine cervical cancer with a third-generation oncolytic herpes simplex virus in combination with an immune checkpoint inhibitor |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916424/ https://www.ncbi.nlm.nih.gov/pubmed/36768352 http://dx.doi.org/10.3390/ijms24031988 |
work_keys_str_mv | AT kagabumasahiro treatmentofhpvrelateduterinecervicalcancerwithathirdgenerationoncolyticherpessimplexvirusincombinationwithanimmunecheckpointinhibitor AT yoshinonaoto treatmentofhpvrelateduterinecervicalcancerwithathirdgenerationoncolyticherpessimplexvirusincombinationwithanimmunecheckpointinhibitor AT murakamikazuyuki treatmentofhpvrelateduterinecervicalcancerwithathirdgenerationoncolyticherpessimplexvirusincombinationwithanimmunecheckpointinhibitor AT kawamurahideki treatmentofhpvrelateduterinecervicalcancerwithathirdgenerationoncolyticherpessimplexvirusincombinationwithanimmunecheckpointinhibitor AT sasakiyutaka treatmentofhpvrelateduterinecervicalcancerwithathirdgenerationoncolyticherpessimplexvirusincombinationwithanimmunecheckpointinhibitor AT murakiyasushi treatmentofhpvrelateduterinecervicalcancerwithathirdgenerationoncolyticherpessimplexvirusincombinationwithanimmunecheckpointinhibitor AT babatsukasa treatmentofhpvrelateduterinecervicalcancerwithathirdgenerationoncolyticherpessimplexvirusincombinationwithanimmunecheckpointinhibitor |